Glycolipid-peptide conjugate vaccines elicit CD8⁺ T-cell responses and prevent breast cancer metastasis.

ABSTRACT:

Objectives

Metastasis is the principal cause of breast cancer mortality. Vaccines targeting breast cancer antigens have yet to demonstrate clinical efficacy, and there remains an unmet need for safe and effective treatment to reduce the risk of metastasis, particularly for people with triple-negative breast cancer (TNBC). Certain glycolipids can act as vaccine adjuvants by specifically stimulating natural killer T (NKT) cells to provide a universal form of T-cell help.

Methods

We designed and made a series of conjugate vaccines comprising a prodrug of the NKT cell-activating glycolipid α-galactosylceramide covalently linked to tumor-expressed peptides, and assessed these using E0771- and 4T1-based breast cancer models in vivo. We employed peptides from the model antig

SUBMITTER: Burn OK 

PROVIDER: S-EPMC9250805 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature